Last reviewed · How we verify
Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis
Approved treatments
- Chronic- PF-06480605 150 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis treatment landscape brief
- Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis treatment updates RSS
Frequently asked questions about Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis
What drugs treat Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis?
Tracked treatments include Chronic- PF-06480605 150 mg SC Q4W.
What is the treatment for Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis?
Standard treatment for Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis includes Chronic- PF-06480605 150 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis patent cliff · Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis CI report
- Treatment: Chronic- PF-06480605 150 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing